2-Hydroxypropyl-beta-cyclodextrin improves the effectiveness of albendazole against encapsulated larvae of Trichinella spiralis in a murine model.
OBJECTIVE
We evaluated whether the effectiveness of albendazole against encapsulated larvae increases when 2-hydroxypropyl-beta-cyclodextrin (HP-betaCD) is added to improve bioavailability.


METHODS
Mice were infected with Trichinella spiralis and treated with albendazole alone, albendazole plus HP-betaCD or not at all (controls) (Experiment I). Both immediately after treatment [76 days post-infection (p.i.)] and later (139 days p.i.) larvae were recovered, and the mean count was expressed in proportion to the larva count for controls. To evaluate the infectivity of the recovered larvae, the larvae recovered at 76 days p.i. and 139 days p.i. were used to infect another three groups (Experiments II and III, respectively).


RESULTS
At 76 days p.i., the percentage of larvae recovered was 77.4% for mice treated with albendazole alone and 61.2% for those treated with albendazole plus HP-betaCD; at 139 days p.i., these percentages were 67.4% and 40.9%, respectively (Experiment I). In Experiments II and III, the percentage of larvae collected from the albendazole group and the combined-treatment group was 55.2% and 27.6%, and 53.1% and 26.6%, respectively. The ABZSO active metabolite was analysed to determine the bioavailability of albendazole. For the combined-treatment group, the area under the plasma concentration-time curve between 0 and 6 h was higher than that for the albendazole group.


CONCLUSIONS
These data suggest that HP-betaCD increases the bioavailability and consequently the effectiveness of albendazole against encapsulated Trichinella larvae.
Casulli
Adriano
A
Department of Infectious, Parasitic and Immunomediated Diseases Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy.
Morales
Maria Angeles Gomez
MA
Gallinella
Bruno
B
Turchetto
Luciana
L
Pozio
Edoardo
E
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D015766:Albendazole / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005079:Excipients / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007814:Larva / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D016896:Treatment Outcome; D017160:Trichinella spiralis / Q000187:drug effects* / Q000254:growth & development; D014235:Trichinellosis / Q000188:drug therapy* / Q000469:parasitology; D047392:beta-Cyclodextrins / Q000008:administration & dosage / Q000627:therapeutic use*
D000871:Anthelmintics; D005079:Excipients; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D015766:Albendazole